Celldex Therapeutics, Inc. (CLDX)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-07

Key Insights

Company is a large accelerated filer in the biotechnology sector with operations focused on immunotherapy programs including CDX-622, Barzvolvolimab (anti-KIT), and other pipeline candidates as of Q1 2026.
Filing shows multiple equity financing activities including an underwritten public offering completed in April 2026 (post-quarter end), indicating the company is actively raising capital to fund operations and clinical development.
The company maintains contingent milestone obligations related to Kolltan Pharmaceuticals acquisition (dating back to 2016 and 2022), suggesting potential future payments based on development or commercial achievements of acquired assets.
Company has registered securities under an equity offering sales agreement as of March 31, 2026, demonstrating ongoing capital market access for funding needs as a development-stage biopharmaceutical company.

Current Report Filed: 2026-05-07

Key Insights

Celldex announced Q1 2026 financial results on May 7, 2026, triggering disclosure requirements under Item 2.02 of Form 8-K for results of operations and financial condition.
The press release is furnished as an exhibit but explicitly not filed under Section 18 of the Exchange Act, limiting liability exposure for forward-looking statements and other disclosures.
The filing was signed by Sam Martin, Senior Vice President and Chief Financial Officer, indicating proper authorization and corporate governance procedures were followed.
As a Nasdaq Capital Market-listed company, Celldex maintains standard SEC reporting obligations but does not qualify as an emerging growth company with extended transition periods.

Current Report Filed: 2026-04-02

Key Insights

Celldex Therapeutics is raising $282 million through a public offering of 10.3 million shares at $29 per share, which could provide additional funding for the company's drug development pipeline.
The underwriters have a 30-day option to purchase up to an additional 1.6 million shares, which could increase the total capital raised.
The timing of the offering, shortly after Celldex's annual 10-K filing, suggests the company may be looking to fund new initiatives or accelerate ongoing research and development programs.

Annual Report Filed: 2026-02-25

Key Insights

Celldex Therapeutics reported consistent revenue growth across its key programs, including Cdx622 and Barzolvolimab Anti-Kit, indicating strong pipeline progress.
The company's investment in research and development, as well as general and administrative expenses, suggests a focus on advancing its drug candidates through clinical development.
Celldex's collaborations with institutions like Rockefeller University and Yale University highlight its commitment to strategic partnerships to drive innovation.

Current Report Filed: 2026-02-25

Key Insights

Celldex Therapeutics reported its Q4 2025 and full-year 2025 financial results, which appear to be in line with expectations.
The company did not provide any material updates or new developments in its press release, suggesting an absence of significant news for investors.
With no major catalysts or surprises, this 8-K filing seems to be a routine quarterly earnings report without major implications for Celldex's outlook.

Insider Trading Filed: 2026-01-06

Key Insights

Samuel Bates Martin, the SVP and CFO of Celldex Therapeutics, Inc. (CLDX), exercised 4,817 stock options at $10.38 per share on January 2, 2026, increasing his direct ownership in the company to 32,942 shares.
The stock options were part of an incentive compensation plan that was fully vested as of June 18, 2024, indicating a long-term alignment between the CFO and shareholders.
The transaction suggests the CFO's confidence in the company's prospects, as he has chosen to hold on to the shares rather than sell them immediately.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.